229 related articles for article (PubMed ID: 31274831)
1. Effects of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Cerulein-Induced Pancreatitis.
Ahmad A; Haas De Mello A; Szczesny B; Törö G; Marcatti M; Druzhyna N; Liaudet L; Tarantini S; Salomao R; Garcia Soriano F; Szabo C
Shock; 2020 May; 53(5):653-665. PubMed ID: 31274831
[TBL] [Abstract][Full Text] [Related]
2. The PARP inhibitor olaparib exerts beneficial effects in mice subjected to cecal ligature and puncture and in cells subjected to oxidative stress without impairing DNA integrity: A potential opportunity for repurposing a clinically used oncological drug for the experimental therapy of sepsis.
Ahmad A; Vieira JC; de Mello AH; de Lima TM; Ariga SK; Barbeiro DF; Barbeiro HV; Szczesny B; Törö G; Druzhyna N; Randi EB; Marcatti M; Toliver-Kinsky T; Kiss A; Liaudet L; Salomao R; Soriano FG; Szabo C
Pharmacol Res; 2019 Jul; 145():104263. PubMed ID: 31071432
[TBL] [Abstract][Full Text] [Related]
3. The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury.
Ahmad A; Olah G; Herndon DN; Szabo C
Br J Pharmacol; 2018 Jan; 175(2):232-245. PubMed ID: 28146604
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-Ribose) Polymerase 1 Promotes Inflammation and Fibrosis in a Mouse Model of Chronic Pancreatitis.
El-Hamoly T; Hajnády Z; Nagy-Pénzes M; Bakondi E; Regdon Z; Demény MA; Kovács K; Hegedűs C; Abd El-Rahman SS; Szabó É; Maléth J; Hegyi P; Virág L
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808340
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of poly(ADP-ribose) polymerase attenuates the severity of acute pancreatitis and associated lung injury.
Mota RA; Sánchez-Bueno F; Saenz L; Hernández-Espinosa D; Jimeno J; Tornel PL; Martínez-Torrano A; Ramírez P; Parrilla P; Yélamos J
Lab Invest; 2005 Oct; 85(10):1250-62. PubMed ID: 16127429
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib, prevents acute lung injury associated cognitive deficits potentially through suppression of inflammatory response.
Sahu B; Narota A; Naura AS
Eur J Pharmacol; 2020 Jun; 877():173091. PubMed ID: 32234526
[TBL] [Abstract][Full Text] [Related]
7. Olaparib: A Clinically Applied PARP Inhibitor Protects from Experimental Crohn's Disease and Maintains Barrier Integrity by Improving Bioenergetics through Rescuing Glycolysis in Colonic Epithelial Cells.
Kovács D; Vántus VB; Vámos E; Kálmán N; Schicho R; Gallyas F; Radnai B
Oxid Med Cell Longev; 2021; 2021():7308897. PubMed ID: 34567413
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib ameliorates influenza-virus-induced pneumonia in mice.
Liu W; Ren X; Wang Q; Zhang Y; Du J
Eur J Clin Microbiol Infect Dis; 2021 Jan; 40(1):159-167. PubMed ID: 32865668
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function.
Ghonim MA; Pyakurel K; Ibba SV; Al-Khami AA; Wang J; Rodriguez P; Rady HF; El-Bahrawy AH; Lammi MR; Mansy MS; Al-Ghareeb K; Ramsay A; Ochoa A; Naura AS; Boulares AH
J Transl Med; 2015 Jul; 13():225. PubMed ID: 26169874
[TBL] [Abstract][Full Text] [Related]
10. Effects of the PARP Inhibitor Olaparib on the Response of Human Peripheral Blood Leukocytes to Bacterial Challenge or Oxidative Stress.
Santos SS; Brunialti MKC; Rodrigues LOCP; Liberatore AMA; Koh IHJ; Martins V; Soriano FG; Szabo C; Salomão R
Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740913
[TBL] [Abstract][Full Text] [Related]
11. PARP-1 inhibition ameliorates elastase induced lung inflammation and emphysema in mice.
Dharwal V; Naura AS
Biochem Pharmacol; 2018 Apr; 150():24-34. PubMed ID: 29355504
[TBL] [Abstract][Full Text] [Related]
12. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
Han C; McNamara B; Bellone S; Harold J; Manara P; Hartwich TMP; Mutlu L; Yang-Hartwich Y; Zipponi M; Demirkiran C; Verzosa MSZ; Altwerger G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Dottino PR; Schwartz PE; Santin AD
Gynecol Oncol; 2023 Mar; 170():172-178. PubMed ID: 36706643
[TBL] [Abstract][Full Text] [Related]
13. PARP Inhibitor Protects Against Chronic Hypoxia/Reoxygenation-Induced Retinal Injury by Regulation of MAPKs, HIF1α, Nrf2, and NFκB.
Kovacs K; Vaczy A; Fekete K; Kovari P; Atlasz T; Reglodi D; Gabriel R; Gallyas F; Sumegi B
Invest Ophthalmol Vis Sci; 2019 Apr; 60(5):1478-1490. PubMed ID: 30973576
[TBL] [Abstract][Full Text] [Related]
14. PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice.
Ghonim MA; Pyakurel K; Ibba SV; Wang J; Rodriguez P; Al-Khami AA; Lammi MR; Kim H; Zea AH; Davis C; Okpechi S; Wyczechowska D; Al-Ghareeb K; Mansy MS; Ochoa A; Naura AS; Boulares AH
Clin Sci (Lond); 2015 Dec; 129(11):951-62. PubMed ID: 26205779
[TBL] [Abstract][Full Text] [Related]
15. PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.
Mukhopadhyay P; Horváth B; Rajesh M; Varga ZV; Gariani K; Ryu D; Cao Z; Holovac E; Park O; Zhou Z; Xu MJ; Wang W; Godlewski G; Paloczi J; Nemeth BT; Persidsky Y; Liaudet L; Haskó G; Bai P; Boulares AH; Auwerx J; Gao B; Pacher P
J Hepatol; 2017 Mar; 66(3):589-600. PubMed ID: 27984176
[TBL] [Abstract][Full Text] [Related]
16. Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer.
Lai SW; Bamodu OA; Chen JH; Wu AT; Lee WH; Chao TY; Yeh CT
Cells; 2020 Apr; 9(4):. PubMed ID: 32276472
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination-Proficient Pancreatic Cancer.
Parsels LA; Engelke CG; Parsels J; Flanagan SA; Zhang Q; Tanska D; Wahl DR; Canman CE; Lawrence TS; Morgan MA
Mol Cancer Ther; 2021 Feb; 20(2):263-273. PubMed ID: 33268569
[TBL] [Abstract][Full Text] [Related]
18. Poly(ADP-ribose) polymerase inhibition suppresses inflammation and promotes recovery from adrenal injury in a rat model of acute necrotizing pancreatitis.
Yu J; Zuo T; Deng W; Shi Q; Ma P; Chen C; Zhao L; Zhao K; Wang W
BMC Gastroenterol; 2016 Jul; 16(1):81. PubMed ID: 27465581
[TBL] [Abstract][Full Text] [Related]
19. Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the early phase after heart transplantation in rats.
Korkmaz-Icöz S; Szczesny B; Marcatti M; Li S; Ruppert M; Lasitschka F; Loganathan S; Szabó C; Szabó G
Br J Pharmacol; 2018 Jan; 175(2):246-261. PubMed ID: 28806493
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
